CompletedPhase 2NCT00851409

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

Studying Hereditary angioedema

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pharming Technologies B.V.
Principal Investigator
Bruno Giannetti, MD
COO Pharming
Intervention
Recombinant Human C1 Inhibitor(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
2009 – 2010

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00851409 on ClinicalTrials.gov

Other trials for Hereditary angioedema

Additional recruiting or active studies for the same condition.

See all trials for Hereditary angioedema →

← Back to all trials